Enlivex Therapeutics (NASDAQ:ENLV) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of Enlivex Therapeutics (NASDAQ:ENLV) to a strong sell rating in a research note released on Saturday morning.

Several other analysts also recently commented on the stock. D Boral Capital downgraded shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Enlivex Therapeutics in a research note on Tuesday, September 2nd. D. Boral Capital restated a “hold” rating on shares of Enlivex Therapeutics in a report on Monday, November 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Enlivex Therapeutics Trading Down 0.4%

ENLV stock opened at $0.74 on Friday. The stock has a 50-day moving average price of $0.97 and a 200-day moving average price of $1.10. Enlivex Therapeutics has a 1-year low of $0.73 and a 1-year high of $2.10. The firm has a market cap of $18.09 million, a PE ratio of -1.35 and a beta of 1.49.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its earnings results on Friday, November 14th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. On average, analysts forecast that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Institutional Trading of Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ENLV. Susquehanna International Group LLP bought a new position in shares of Enlivex Therapeutics in the third quarter valued at $57,000. Jane Street Group LLC raised its holdings in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after acquiring an additional 67,886 shares during the last quarter. Finally, Citizens Financial Group Inc. RI acquired a new stake in shares of Enlivex Therapeutics in the 3rd quarter worth about $241,000. Institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.